Jairam Krishnamurthy, MD, FACP, discusses the use of mutation status to inform treatment sequencing in HR-positive, HER2-negative metastatic breast cancer.
Jairam Krishnamurthy, MD, FACP
Advertisement
Articles by Jairam Krishnamurthy, MD, FACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5